Do you know your way around the Lauer Taxe? – A quick-start help guide
The Lauer Taxe is a database of all pharmaceutical entities, e.g. drugs, medical devices and also remedies, and their prices.
Category: News and updates
Confused about drug prices in Germany? This post will help you gain clarity
In this post, I am discussing the different types of prices, price discounts and rebates, and who is paying what.
The four most important things to know about pricing in Germany
Currently, in Germany, free pricing applies in the first year. This means, at the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a new chemical entity (NCE). This price is then valid for the first 12 months from the day of launch.
The G-BA will collaborate on joint EU HTAs
In July 2021, we had heard that the G-BA had agreed to joint EU HTAs coming to Germany. Now, on 14 December
Switching between original biologics and biosimilars in Germany
Biosimilars are biological drugs that are highly similar to another biological medicine, the so-called originator. The biosimilars have no clinically meaningful differences to
The G-BA increases the fees for consultations
Manufacturers of drugs or medical devices can apply for a consultation meeting with the G-BA before submitting a dossier. This consultation offers
Prof. Dr. Karl Lauterbach is the new German health minister
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot
New government coalition plans AMNOG, pricing and other reforms
The new government in Germany is formed as a coalition of the three parties, SDP, FDP and the Green Party. At the
The biggest SHI fund, the AOK, proposes an end to free pricing in Germany
Currently, free pricing of products with a new chemical entity (NCE) applies in the first year. This means, at the time of
Experience with DiGA fast track process in Germany after one year
The BfArM assesses medical apps and digital health treatments (DiGA) in terms of patient benefit, positive effects on care, data protection and